3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Gastrointestinal Stromal Tumors
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neurofibrosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pazopanib
3
pembrolizumab
2
Sirolimus
2
temsirolimus
1
selinexor
1
sapanisertib
1
pexidartinib
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
STA 9090
1
Proton Therapy
1
Imatinib Mesylate
1
Ifosfamide
1
HhAntag691
1
Doxorubicin
1
Docetaxel
1
AZD 6244
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neurofibrosarcoma
×
pexidartinib
×
Clear all
NCT02584647
2025-03-21
PLX3397
Columbia University
Phase 1/2
Terminated
39 enrolled
13 charts